The strong U.S. launch trajectory for IMCIVREE in acquired HO, with 29% sequential revenue growth and expanding prescriber base, supports continued top-line acceleration. The $750M term loan facility provides substantial capital to fund pipeline advancement, including Phase 3 trials for bivamelagon in both acquired HO and Prader-Willi syndrome, while the LG Chem amendment reduces future royalty drag. Monitor European country-level launches beginning in 2027 and Japan launch uptake as additional catalysts.
Drug in focus
RYTM drug pipeline →IMCIVREE
▲ Bullish Named in this 8-K- Impact
- Not rated
- Phase
- Not stated
- Time to market
- Not stated
- Next catalyst
- None dated
Price Chart
Executive Summary
Rhythm Pharmaceuticals reported Q3 2026 product revenue of $92.1M, well above the $84.6M consensus, driven by a strong U.S. launch of IMCIVREE in acquired hypothalamic obesity. Net loss per share of -$0.61 beat the -$0.74 consensus estimate. The company also secured a $750M term loan facility and amended its bivamelagon license with LG Chem, reducing the royalty rate to 1% in exchange for $350M in fixed payments.
Key Financial Metrics
Key Facts
- Q3 2026 net product revenue of $92.1M, up 29% sequentially from Q2 2026 and 80% YoY from $51.3M in Q3 2025
- Net loss attributable to common stockholders of -$42.4M, or -$0.61 per share, compared to -$54.3M or -$0.82 per share in Q3 2025
- More than 700 patient start forms for IMCIVREE in acquired HO as of September 30, 2026, from more than 500 prescribers
- Entered into a five-year term loan facility providing access to up to $750M, with an initial $250M draw
- Amended bivamelagon license with LG Chem: $350M in fixed payments over four years to reduce royalty to 1% on MC4R portfolio sales
- Cash, cash equivalents and short-term investments of $320.9M as of September 30, 2026, excluding the $250M loan draw and $70M LG Chem payment
- 2026 Non-GAAP Operating Expense guidance narrowed to $360M-$380M from prior $363M-$397M
Financial Impact
Q3 revenue of $92.1M beat consensus of $84.6M by 8.9%; EPS of -$0.61 beat consensus of -$0.74 by 17.6%
Risk Factors
- Dependence on successful commercial execution of IMCIVREE in acquired HO, a newly approved indication
- Significant increase in SG&A expenses (up 27% YoY) related to U.S. and Japan launches, which may pressure margins
- Execution risk for Phase 3 trials of bivamelagon and RM-718, and potential for clinical setbacks
- $350M fixed payment obligation to LG Chem over four years adds to cash burn
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-069106 |
| Document: 0001628280-26-069106-index-headers.html | 0001628280-26-069106 |
| Document: 0001628280-26-069106-index.html | 0001628280-26-069106 |
| Document: 0001628280-26-069106.txt | 0001628280-26-069106 |
| 8-K Data (Synthetic) | 0001628280-26-069106 |
Track record
26 reports on RYTM
9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 Viewing No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers